United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2016_register executive 2018-02-07 article Notices D09002ee1c7f655f1 D09002ee1c7f65671 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a start-up exclusive license to AestasRx Inc., which is located in North Carolina, to practice the inventions embodied in the following patents: U.S. Patent 8,597,660, issued December 3, 2013 (HHS reference E-144-2010/0- US-02). The patent rights in these inventions have been assigned to the United States of America. The prospective start-up exclusive license territory may be worldwide and the field of use may be limited to therapeutics (including small-molecule TFP5 mimetics) and PMA-approved diagnostics for Alzheimer's disease (intranasal delivery only), Parkinson's Disease, neuropathy, neuropathic pain, peripheral neuropathy, diabetic neuropathy, neurapraxia, axonotmesis and neurotmesis. 81 FR 20658 https://www.govinfo.gov/app/details/FR-2016-04-08/2016-08097 2016-08097 fr08ap16-90 4140-01-P https://www.govinfo.gov/app/details/FR-2016-04-08/2016-08097 https://www.govinfo.gov/content/pkg/FR-2016-04-08/html/2016-08097.htm https://www.govinfo.gov/content/pkg/FR-2016-04-08/pdf/2016-08097.pdf 1 p. 20658 20658 81 FR 20658 Prospective Grant of Start-up Exclusive License: Therapeutics and PMA-Approved Diagnostics for Alzheimer's Disease (intranasal delivery), Parkinson's Disease, Neuropathy,Neuropathic Pain, Peripheral Neuropathy, Diabetic Neuropathy, Neurapraxia, Axonotmesis and Neurotmesis; Federal Register Vol. 81, Issue NOTICE 2016-08097 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2016-04-25 4140-01-P 2016-08097 Notice.

This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a start-up exclusive license to AestasRx Inc., which is located in North Carolina, to practice the inventions embodied in the following patents: U.S. Patent 8,597,660, issued December 3, 2013 (HHS reference E-144-2010/0- US-02). The patent rights in these inventions have been assigned to the United States of America. The prospective start-up exclusive license territory may be worldwide and the field of use may be limited to therapeutics (including small-molecule TFP5 mimetics) and PMA-approved diagnostics for Alzheimer's disease (intranasal delivery only), Parkinson's Disease, neuropathy, neuropathic pain, peripheral neuropathy, diabetic neuropathy, neurapraxia, axonotmesis and neurotmesis.

Only written comments and/or applications for a license which are received by NINDS Technology Transfer on or before April 25, 2016 will be considered. Exclusive Licenses: Therapeutics and PMA-approved Diagnostics for Alzheimer's Disease (Intranasal Delivery), etc. , anos@mail.nih.gov Vol. 81, no. 68 Office of the Federal Register, National Archives and Records Administration 2016-04-08 continuing daily deposited born digital 708 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2016-04-08 P0b002ee1985946e9 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr08ap16 https://www.govinfo.gov/app/details/FR-2016-04-08 https://www.govinfo.gov/content/pkg/FR-2016-04-08/pdf/FR-2016-04-08.pdf https://www.govinfo.gov/content/pkg/FR-2016-04-08/xml/FR-2016-04-08.xml fdlp 20523 21221 DGPO 2018-02-07 2024-06-02 FR-2016-04-08 machine generated eng FR FR-2016-04-08 81 68